Get the Stockscreener App
0.6407
19.76%
0.1057
Salarius Pharmaceuticals Inc stock is traded at $0.6407, with a volume of 681.52K.
It is up +19.76% in the last 24 hours and down -22.34% over the past month.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
See More
Previous Close:
$0.535
Open:
$0.5189
24h Volume:
681.52K
Relative Volume:
0.39
Market Cap:
$3.76M
Revenue:
$4.70M
Net Income/Loss:
$-4.99M
P/E Ratio:
-0.0998
EPS:
-6.42
Net Cash Flow:
$-5.29M
1W Performance:
-1.07%
1M Performance:
-22.34%
6M Performance:
-95.19%
1Y Performance:
-97.63%
1-Day Range:
$0.5153
$0.6587
1-Week Range:
$0.5148
$0.6764
52-Week Range:
$0.5148
$108.00
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Name
Salarius Pharmaceuticals Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare SLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.6407 | 3.14M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.04 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.71 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.07 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.66 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.78 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Stock (SLRX) Latest News
Salarius Pharmaceuticals (NASDAQ:SLRX) Downgraded by Wall Street Zen to Sell - Defense World
Salarius Pharmaceuticals Inc. (SLRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting - Investing.com Nigeria
Salarius Shareholders Back Directors, Executive Pay and Auditor - TipRanks
Salarius Pharmaceuticals Appeals Nasdaq Delisting After Bid Deficiency - TipRanks
Salarius Pharmaceuticals faces potential Nasdaq delisting after bid price rule breach By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting By Investing.com - Investing.com South Africa
Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Nigeria
Hanish, director at Salarius, sells shares worth $17 - Investing.com
Salarius Pharmaceuticals (NASDAQ: SLRX) appeals Nasdaq delisting over $1.00 bid rule - Stock Titan
Salarius shareholders back directors, executive pay and auditor - MSN
Salarius announces planned corporate name change to Decoy Therapeutics - MSN
Salarius Pharmaceuticals stock tumbles after announcing $7 million discounted public offering - MSN
Can Salarius Pharmaceuticals Inc. stock hit analyst price targets2025 Valuation Update & Fast Moving Market Watchlists - Улправда
Wall Street Recap: Can Salarius Pharmaceuticals Inc. (FP10) stock hit consensus price targetsWeekly Market Report & Fast Entry Momentum Alerts - Улправда
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting - The Manila Times
Salarius Pharmaceuticals adjourns annual meeting over quorum shortfall - MSN
Investment Review: Will Salarius Pharmaceuticals Inc. stock benefit from infrastructure spendingWeekly Trading Summary & Fast Moving Stock Watchlists - Улправда
Salarius Pharmaceuticals Adjourns Annual Meeting Over Quorum Shortfall - TipRanks
Salarius Pharmaceuticals adjourns annual meeting due to low turnout By Investing.com - Investing.com Nigeria
Can Salarius Pharmaceuticals Inc. (FP10) stock hit consensus price targets2025 EndofYear Setup & Expert Verified Stock Movement Alerts - Улправда
Salarius Pharmaceuticals adjourns annual meeting due to low turnout - Investing.com
Is Salarius Pharmaceuticals Inc. stock gaining market share2025 Retail Activity & Stock Portfolio Risk Management - DonanımHaber
What dividend safety rating applies to Salarius Pharmaceuticals Inc. (FP10) stockPortfolio Return Report & Fast Gain Stock Tips - DonanımHaber
Is Salarius Pharmaceuticals Inc. stock affected by interest rate hikesWeekly Market Summary & Detailed Earnings Play Alerts - Улправда
What makes Salarius Pharmaceuticals Inc. stock attractive to growth fundsSwing Trade & Real-Time Stock Entry Alerts - DonanımHaber
Barbara Louise Hibner Net Worth (2025) - GuruFocus
Salarius to change name to Decoy Therapeutics, adopt DCOY ticker By Investing.com - Investing.com Nigeria
Salarius Pharmaceuticals to Change Name to Decoy Therapeutics - marketscreener.com
Salarius Pharmaceuticals (SLRX) to Rebrand as Decoy Therapeutics - GuruFocus
SLRX Insider Trading - Quiver Quantitative
Salarius to change name to Decoy Therapeutics, adopt DCOY ticker - Investing.com
Salarius Pharmaceuticals announces name and ticker change to Decoy Therapeutics - marketscreener.com
Salarius Pharmaceuticals, Inc. Transforms into Decoy Therapeutics, Inc. with NASDAQ Ticker Change to DCOY Effective January 2026 - Quiver Quantitative
Decoy Therapeutics pivots to next-gen antivirals for multi-virus threats - Stock Titan
NanOlogy names David Arthur as CEO - Fort Worth Report
Salarius Pharmaceuticals Earnings Notes - Trefis
Taking the lead: Salarius Pharmaceuticals Inc (SLRX) - setenews.com
Salarius Pharmaceuticals (NASDAQ:SLRX) Upgraded at Wall Street Zen - Defense World
Why Salarius Pharmaceuticals Inc. stock is a must watch in 20252025 Trade Ideas & Real-Time Chart Breakout Alerts - Newser
Can Salarius Pharmaceuticals Inc. (FP10) stock resist broad market declinesTrend Reversal & Accurate Entry/Exit Alerts - Newser
Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):